Allarity Therapeutics (ALLR) vs Tvardi Therapeutics (TVRD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Allarity Therapeutics (ALLR) has outperformed Tvardi Therapeutics (TVRD) over the past year, losing 42.2% versus a loss of 97.3%. Allarity Therapeutics is the larger company by market cap ($16.0 million vs $13.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLR | TVRD |
|---|---|---|
| Share price | $1.01 | $1.05 |
| Market cap | $15.99M | $13.94M |
| 1-day change | +2.35% | -3.24% |
| YTD return | -9.08% | -74.88% |
| 1-year return | -42.24% | -97.29% |
| 5-year return | — | -99.77% |
| EPS (TTM) | $-0.79 | $-2.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.84 | $43.65 |
| 52-week low | $0.769 | $0.93 |
| Distance from 52-week high | -45.38% | -97.61% |
| Analyst consensus | none | buy |
| Avg. price target upside | +994.53% | +785.17% |
| Average volume | 90.75K | 424.45K |
| Shares outstanding | 15.91M | 13.34M |
| Employees | 7 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALLR has outperformed TVRD by 55.1 percentage points over the past year.
About Allarity Therapeutics
ALLR stock →Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Tvardi Therapeutics
TVRD stock →Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
ALLR vs TVRD FAQ
Which is bigger, Allarity Therapeutics or Tvardi Therapeutics?
Allarity Therapeutics (ALLR) is larger, with a market capitalization of $15.99M compared with $13.94M for Tvardi Therapeutics (TVRD).
Which stock has performed better over the past year, ALLR or TVRD?
ALLR returned -42.24% over the past 12 months, compared with -97.29% for TVRD (price return, excluding dividends). Past performance does not predict future results.
Are Allarity Therapeutics and Tvardi Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.